

GP-3763


A-596164/ENB

DB

#17

CERTIFICATE OF MAIL UNDER 37 CFR 1.10

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on June 12, 2002.



Signed

Edward N. Bachand

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  
INGEMAR H. LUNDQUIST et al.

Serial No.: 09/553,738  
Filing Date: April 20, 2000

Title: TREATMENT DEVICE WITH  
GUIDABLE NEEDLE

Art Unit: 3763  
Examiner: Michael M. Thompson  
Date: June 12, 2002

RECEIVED  
JUN 25 2002  
TC 3700 MAIL ROOM

AMENDMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Dear Sir:

This Amendment is in response to the Office Action mailed March 12, 2002.

REMARKS

Applicants noted in their responsive Amendment filed May 7, 2001 and in their responsive Amendment filed November 4, 2001 that the Information Disclosure Statement mailed April 20, 2000, a copy of which is enclosed herewith, did not appear to have been considered by the Examiner. The Action mailed July 31, 2001 includes only Page 8 of the eight pages of references included in the April 20 Information Disclosure Statement. Applicants respectfully request that the Examiner confirm that the other seven pages of references included in the April 20 Information Disclosure Statement have been considered by him.

Claims 14-18 and 23-28 have been rejected under 35 U.S.C. §102(b) as being anticipated by Orandi (U.S. Patent No. 4,524,770). Claims 19-22 and 29-30 have been rejected under 35 U.S.C. §103(a) as being unpatentable over Orandi in view of LeVeen (U.S. Patent No. 3,991,770). Reconsideration of these claims is respectfully requested.

Orandi discloses an endoscope injection needle. Tool 10 is comprised of a needle 12